Related references
Note: Only part of the references are listed.Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort
Christoph Hoener Zu Siederdissen et al.
CLINICAL INFECTIOUS DISEASES (2016)
Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors
Amit Khatri et al.
CLINICAL INFECTIOUS DISEASES (2016)
Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals
Rebecca Cope et al.
AIDS PATIENT CARE AND STDS (2015)
Hepatitis C Virus Therapeutic Development: In Pursuit of Perfectovir
Gregory J. Dore et al.
CLINICAL INFECTIOUS DISEASES (2015)
Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection
Anu Osinusi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1 A Randomized Trial
Mark S. Sulkowski et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
EASL Recommendations on Treatment of Hepatitis C 2015
JOURNAL OF HEPATOLOGY (2015)
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study
Jean-Michel Molina et al.
LANCET (2015)
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
Mohsen Naghavi et al.
LANCET (2015)
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Susanna Naggie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
D. L. Wyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients
Isabelle Poizot-Martin et al.
PLOS ONE (2015)
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial
Juergen K. Rockstroh et al.
LANCET HIV (2015)
Global epidemiology and genotype distribution of the hepatitis C virus infection
Erin Gower et al.
JOURNAL OF HEPATOLOGY (2014)
Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis
Marisa Montes et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2014)
Mortality in Hepatitis C Virus-Infected Patients With a Diagnosis of AIDS in the Era of Combination Antiretroviral Therapy
Andrea D. Branch et al.
CLINICAL INFECTIOUS DISEASES (2012)
Sustained Virological Response to Interferon Plus Ribavirin Reduces Non-Liver-Related Mortality in Patients Coinfected With HIV and Hepatitis C Virus
Juan Berenguer et al.
CLINICAL INFECTIOUS DISEASES (2012)
All-cause and liver-related mortality in HIV positive subjects compared to the general population: Differences by HCV co-infection
Victoria Hernando et al.
JOURNAL OF HEPATOLOGY (2012)
Randomized Trial Comparing Pegylated Interferon alpha-2b Versus Pegylated Interferon alpha-2a, Both Plus Ribavirin, to Treat Chronic Hepatitis C in Human Immunodeficiency Virus Patients
Montserrat Laguno et al.
HEPATOLOGY (2009)
Diagnosis, Management, and Treatment of Hepatitis C: An Update
Marc G. Ghany et al.
HEPATOLOGY (2009)
HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis
JA Pineda et al.
HEPATOLOGY (2005)
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C
M Ziol et al.
HEPATOLOGY (2005)
Share Paper
